Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

BUY
$12.46 - $29.95 $11.2 Million - $26.9 Million
896,600 Added 122.05%
1,631,240 $48.4 Million
Q3 2023

Nov 14, 2023

SELL
$14.09 - $19.87 $6.81 Million - $9.61 Million
-483,400 Reduced 39.69%
734,640 $11.7 Million
Q2 2023

Aug 11, 2023

BUY
$3.75 - $20.05 $4.27 Million - $22.8 Million
1,138,900 Added 1439.1%
1,218,040 $23 Million
Q1 2023

May 12, 2023

BUY
$3.67 - $4.92 $290,443 - $389,368
79,140 New
79,140 $304,000
Q3 2022

Nov 14, 2022

BUY
$4.48 - $6.47 $1.15 Million - $1.66 Million
256,400 Added 17.7%
1,705,140 $8.15 Million
Q2 2022

Aug 12, 2022

SELL
$3.15 - $5.76 $42,840 - $78,336
-13,600 Reduced 0.93%
1,448,740 $6.52 Million
Q1 2022

May 13, 2022

BUY
$4.26 - $7.48 $1.04 Million - $1.83 Million
244,953 Added 20.12%
1,462,340 $6.96 Million
Q4 2021

Feb 11, 2022

BUY
$4.75 - $7.5 $358,848 - $566,602
75,547 Added 6.62%
1,217,387 $9.03 Million
Q3 2021

Nov 12, 2021

SELL
$5.02 - $6.59 $4.73 Million - $6.21 Million
-942,250 Reduced 45.21%
1,141,840 $6.47 Million
Q2 2021

Aug 13, 2021

BUY
$5.79 - $8.6 $1.28 Million - $1.9 Million
220,750 Added 11.85%
2,084,090 $13.7 Million
Q1 2021

May 13, 2021

SELL
$6.5 - $10.53 $15.4 Million - $25 Million
-2,372,626 Reduced 56.01%
1,863,340 $15.1 Million
Q4 2020

Feb 10, 2021

SELL
$3.7 - $7.66 $8.34 Million - $17.3 Million
-2,253,173 Reduced 34.72%
4,235,966 $27.3 Million
Q3 2020

Nov 13, 2020

SELL
$3.45 - $4.89 $11 Million - $15.5 Million
-3,176,000 Reduced 32.86%
6,489,139 $23.4 Million
Q2 2020

Aug 13, 2020

SELL
$3.32 - $5.34 $4.49 Million - $7.21 Million
-1,350,990 Reduced 12.26%
9,665,139 $44.5 Million
Q1 2020

May 14, 2020

BUY
$2.12 - $6.8 $655,058 - $2.1 Million
308,990 Added 2.89%
11,016,129 $37.6 Million
Q4 2019

Feb 13, 2020

BUY
$2.25 - $5.8 $4.91 Million - $12.7 Million
2,184,100 Added 25.63%
10,707,139 $54.7 Million
Q3 2019

Nov 13, 2019

BUY
$2.22 - $3.39 $3.55 Million - $5.43 Million
1,600,399 Added 23.12%
8,523,039 $20.6 Million
Q2 2019

Aug 12, 2019

SELL
$1.8 - $3.3 $217,800 - $399,300
-121,000 Reduced 1.72%
6,922,640 $15 Million
Q1 2019

May 14, 2019

BUY
$2.41 - $5.91 $2.08 Million - $5.09 Million
861,500 Added 13.94%
7,043,640 $19.1 Million
Q4 2018

Feb 13, 2019

BUY
$3.94 - $9.7 $24.4 Million - $60 Million
6,182,140 New
6,182,140 $29.7 Million

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.